# US 2019/0292265 A1 · Methods of Treating Crohn's Disease with an Anti-NKG2D Antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0292265 A1
- Document ID: US20190292265A1
- Status: Published application
- Kind: A1
- Application number: 16/325,969
- Filed: 2017-08-17
- Published: 2019-09-26
- Earliest claimed: 2016-08-19
- Assignees: Janssen Biotech, Inc.
- Applicants: Janssen Biotech, Inc.
- Inventors: Carrie Brodmerkel; Mark Curran; Linda Greenbaum; Shannon Telesco
- Web page: https://patentgrep.com/patent/US20190292265A1

## CPC

- C07K 16/2851: {against the lectin superfamily, e.g. CD23, CD72}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 37/00: Drugs for immunological or allergic disorders
- C12Q 1/6827: for detection of mutation or polymorphism
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention is directed to methods for treating Crohn's Disease with an antibody that binds NKG2D. In particular, it relates to dosing regimens for administration of an anti-NGK2D antibody. It also relates to methods of selecting patients for treatment with an anti-NKG2D antibody.

## Claims

### Claim 1

A method of treating a human patient with Crohn's disease, the method comprising administering to the human patient a safe and effective amount of an anti-NKG2D antibody comprising CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the sequences set forth in SEQ ID NO: 3, 4 and 5, respectively and CDR1, CDR2 and CDR3 domains of the light chain variable region having the sequences set forth in SEQ ID NO: 6, 7, and 8, respectively, wherein the method comprises at least one administration cycle, wherein for each of the at least one cycle, the anti-NKG2D antibody is administered as follows: (a) one dose of 400 mg anti-NKG2D antibody and (b) at least one dose of 200 mg anti-NKG2D antibody.

### Claim 2 (depends on 1)

The method of claim 1, wherein the anti-NKG2D antibody is formulated for intravenous or subcutaneous administration.

### Claim 3 (depends on 1)

The method of claim 1, wherein the treatment consists of up to 6 cycles.

### Claim 4 (depends on 1)

The method of claim 1, wherein the 200 mg dose is administered eleven times.

### Claim 5 (depends on 1)

The method of claim 1, wherein the administration of dose (b) of the NKG2D antibody is administered once every 2 weeks for 22 weeks.

### Claim 6 (depends on 1)

The method of claim 1, wherein the anti-NKG2D antibody produces an effect in the human patient selected from the group consisting of reduction of a symptom of Crohn's disease, induction of a clinical response, induction or maintenance of clinical remission, inhibition of disease progression and inhibition of a disease complication.

### Claim 7 (depends on 1)

The method of claim 1, wherein the anti-NKG2D antibody produces an effect in the human patient selected from the group consisting of reduction of a Crohn's Disease Activity Index score, decrease in C-Reactive Protein expression level, decrease in fecal calprotein expression level and reduction in the number of open draining fistulas.

### Claim 8 (depends on 7)

The method of claim 7, wherein the Crohn's Disease Activity Index score of the human patient is reduced by at least 100 points.

### Claim 9 (depends on 7)

The method of claim 7, wherein the Crohn's Disease Activity Index score of the human patient is reduced to less than 150.

### Claim 10 (depends on 6)

The method of claim 6, wherein the reduction in a symptom of Crohn's disease is a decrease of at least 50% of open draining fistulas in the human patient.

### Claim 11 (depends on 1)

The method of claim 1, wherein the human patient has been diagnosed with active moderate to severe Crohn's disease prior to the administration of the anti-NKG2D antibody.

### Claim 12 (depends on 1)

The method of claim 1, wherein the human patient has a Crohn's Disease Activity Index score of 220-450 prior to the administration of the anti-NKG2D antibody.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1-12, wherein the human patient has a genotype comprising a single nucleotide polymorphism (SNP) rs2255336 and/or rs2239705 prior to the administration of the anti-NKG2D antibody.

### Claim 14 (depends on 1)

The method of claim 1, wherein the anti-NKG2D antibody comprises a heavy-chain variable region comprising SEQ ID NO: 1 and a light-chain variable region comprising SEQ ID NO: 2.

### Claim 15

A method of treating a human patient with Crohn's disease, the method comprising the steps of:
(a) determining whether the human patient has a SNP in an NKG2D receptor gene or MICB gene by obtaining a biological sample from the human patient and performing a genotyping assay on the biological sample;
(b) administering an anti-NKG2D receptor antibody if the patient has the SNP, wherein the anti-NKG2D antibody comprises CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the sequences set forth in SEQ ID NO: 3, 4 and 5, respectively and CDR1, CDR2 and CDR3 domains of the light chain variable region having the sequences set forth in SEQ ID NO: 6, 7, and 8, respectively.

### Claim 16 (depends on 15)

The method of claim 15, wherein the anti-NKGD2 antibody is administered in at least one cycle comprising the administration of (a) one dose of 400 mg anti-NKG2D antibody and (b) at least one dose of 200 mg anti-NKG2D antibody.

### Claim 17 (depends on 15)

The method of claim 15, wherein the SNP is rs2255336 or rs2239705.
